Carelabs Co., Ltd.

As of June 30, 2026, Carelabs Co., Ltd. carries a market capitalization of 39.87B, placing it among publicly traded companies globally. Its enterprise value stands at 13.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Carelabs Co., Ltd. has 19.40M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.54, and the price-to-book ratio stands at 0.60.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.58B versus a market cap of 39.87B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Carelabs Co., Ltd. maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.49, indicating elevated leverage, while an interest coverage ratio of -3.27 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Carelabs Co., Ltd. posted a negative return on equity (ROE) of -10.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.05, reflecting losses generated across the asset base. The company generates approximately 598.03M in revenue per employee across its workforce of 123.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.48 indicates how many times Carelabs Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Carelabs Co., Ltd. recorded 821.51M in income tax expense. The company reported a pretax loss of -5.84B and -7.30B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Carelabs Co., Ltd.'s stock has declined approximately 52.05% over the past 52 weeks. The 50-day moving average sits at 2,010.08, while the 200-day moving average is 2,305.28.

Over the twelve months ended June 30, 2026, Carelabs Co., Ltd. generated 74.01B in revenue and converted that into -7.30B in net income, yielding earnings per share of -343.67. EBITDA reached -3.63B, while operating income came in at -6.34B.

As of June 30, 2026, Carelabs Co., Ltd. holds 34.79B in cash and equivalents against 2.54B in total debt, resulting in a net debt position of -20.20B. Total book value stands at 66.72B, with working capital of 15.93B providing operational flexibility.

Carelabs Co., Ltd. produced -5.41B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -17.79B in capital expenditures, free cash flow totaled -23.20B - equivalent to -1,196.33 per share.

Over the twelve months ended June 30, 2026, Carelabs Co., Ltd. posted a gross margin of 97.31, reflecting its pricing power and cost economics. The operating margin of -8.57 and net profit margin of -9.87 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Carelabs Co., Ltd. paid dividends of 1.24 per share. The dividend payout ratio of -0.40 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -58.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 5.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Carelabs Co., Ltd. shareholders.

Carelabs Co., Ltd.'s most recent stock split took place on July 16, 2020 with a 1:2 split ratio.

As of June 30, 2026, Carelabs Co., Ltd. has an Altman Z-Score of 1.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.